RSS | Login | Register

Gentamicin Inj

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare Gentamicin Inj to:

Generic Name for Gentamicin Inj

Gentamicin sulfate 40mg/mL; IM, or IV inj after dilution; contains sulfites.

Legal Classification:

Pharmacological Class for Gentamicin Inj

Aminoglycoside.

Manufacturer of Gentamicin Inj

Various generic manufacturers

Indications for Gentamicin Inj

Serious susceptible infections.

Adult dose for Gentamicin Inj

Obesity: Base dose on lean body mass. Usual duration 7–10 days. 1mg/kg IM or IV every 8 hours; max 5mg/kg/day. For alternative dosing regimens (eg, extended intervals) see literature.

Children's dosing for Gentamicin Inj

Premature and infants <1 week: 2.5mg/kg every 12 hours. Neonates: 2.5mg/kg every 8 hours. Others: 2–2.5mg/kg every 8 hours.

Warnings/Precautions for Gentamicin Inj

Monitor for nephro- and neurotoxicity; avoid peak serum levels >12micrograms/mL (when dosed at conventional intervals) and trough levels >2micrograms/mL. Renal impairment: reduce dose, see literature; maintain adequate hydration. Prolonged use or excessive doses. Asthma. Neuromuscular disorders. Elderly. Pregnancy (Cat.D): not recommended.

Interactions for Gentamicin Inj

Avoid concomitant furosemide, ethacrynic acid, other nephro/neurotoxic drugs including cephalosporins. May potentiate neuromuscular blockade.

Adverse Reactions for Gentamicin Inj

Nephro- or neurotoxicity, respiratory depression, lethargy, confusion, depression, visual disturbances, elevated liver enzymes, blood dyscrasias.

How is Gentamicin Inj supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.